Literature DB >> 24692694

Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.

Takahiro Yamauchi1, Kanako Uzui, Rie Nishi, Hiroko Shigemi, Takanori Ueda.   

Abstract

BACKGROUND/AIM: Clofarabine is transported into leukemic cells via the equilibrative nucleoside transporters (hENT) 1 and 2 and the concentrative nucleoside transporter (hCNT) 3, then phosphorylated by deoxycytidine kinase (dCK) and deoxyguanosine kinase (dGK) to an active triphosphate metabolite. Cytarabine uses hENT1 and dCK for its activation. We hypothesized that cytarabine-resistant leukemia cells retain sensitivity to clofarabine.
MATERIALS AND METHODS: Human myeloid leukemia HL-60 cells and cytarabine-resistant variant HL/ara-C20 cells were used in the present study.
RESULTS: Despite 20-fold cytarabine resistance, the HL/ara-C20 cells exhibited only a 6-fold resistance to clofarabine compared to HL-60 cells. The intracellular concentration of the triphosphate metabolite of cytarabine was reduced to 1/10, and that of clofarabine was halved in the HL/ara-C20 cells. hENT1 and dCK were reduced, but hCNT3 and dGK were not altered in the HL/ara-C20 cells, which might contribute to their retained capability to produce intracellular triphosphate metabolite of clofarabine.
CONCLUSION: Clofarabine was cytotoxic to leukemia cells that were resistant to cytarabine.

Entities:  

Keywords:  Clofarabine; acute myeloid leukemia; clofarabine triphosphate; cytarabine; drug resistance

Mesh:

Substances:

Year:  2014        PMID: 24692694

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  A ribonucleotide reductase inhibitor with deoxyribonucleoside-reversible cytotoxicity.

Authors:  Mikael Crona; Paula Codó; Venkateswara Rao Jonna; Anders Hofer; Aristi P Fernandes; Fredrik Tholander
Journal:  Mol Oncol       Date:  2016-07-26       Impact factor: 6.603

2.  Dual anti-HIV mechanism of clofarabine.

Authors:  Michele B Daly; Megan E Roth; Laurent Bonnac; José O Maldonado; Jiashu Xie; Christine L Clouser; Steven E Patterson; Baek Kim; Louis M Mansky
Journal:  Retrovirology       Date:  2016-03-24       Impact factor: 4.602

Review 3.  Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.

Authors:  Nikolaos Tsesmetzis; Cynthia B J Paulin; Sean G Rudd; Nikolas Herold
Journal:  Cancers (Basel)       Date:  2018-07-23       Impact factor: 6.639

4.  Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.

Authors:  Rie Nishi; Hiroko Shigemi; Eiju Negoro; Miyuki Okura; Naoko Hosono; Takahiro Yamauchi
Journal:  BMC Cancer       Date:  2020-10-12       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.